Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Halozyme Therapeutics Trading Down 0.4 %

Shares of NASDAQ HALO traded down $0.22 during midday trading on Thursday, reaching $57.70. The stock had a trading volume of 879,987 shares, compared to its average volume of 1,292,471. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company’s 50 day moving average price is $54.08 and its 200 day moving average price is $54.71. The firm has a market cap of $7.11 billion, a price-to-earnings ratio of 16.82, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Institutional Trading of Halozyme Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $29,000. Smartleaf Asset Management LLC increased its stake in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $69,000. Finally, Farther Finance Advisors LLC raised its holdings in Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,028 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HALO. Benchmark restated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.